CEO: Rich Shea
The medical need in the area of diabetic kidney disease is approaching emergency status. Vascular is focused on the development of therapeutics targeting the treatment of diabetes-associated diseases. The company’s first clinical trials will target diabetic kidney disease. The company was founded with technology created at UNC-Chapel Hill.